Literature DB >> 16471077

Human immunodeficiency virus-associated peripheral neuropathies.

Sergio Ferrari1, Sandro Vento, Salvatore Monaco, Tiziana Cavallaro, Francesca Cainelli, Nicolò Rizzuto, Zelalem Temesgen.   

Abstract

Peripheral neuropathy has emerged as the most common neurologic complication of human immunodeficiency virus (HIV) infection. It will continue to play an Important role in HIV Infection given the fact that HIV-infected Individuals are living longer, are at risk of long-term metabolic complications, and face an Increasing exposure to potentially neurotoxic antiretroviral drugs. We review the various types of peripheral neuropathy that have been associated with HIV infection, including distal symmetrical polyneuropathy, toxic neuropathy from antiretroviral drugs, diffuse infiltrative lymphocytosis syndrome, inflammatory demyelinating polyneuropathies, multifocal mononeuropathies, and progressive polyradiculopathy.

Entities:  

Mesh:

Year:  2006        PMID: 16471077     DOI: 10.4065/81.2.213

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  28 in total

1.  Acute motor axonal neuropathy in HIV infection.

Authors:  Shruti Jadhav; Mukesh Agrawal; Surbhi Rathi
Journal:  Indian J Pediatr       Date:  2013-09-21       Impact factor: 1.967

2.  Prevalence, self-care behaviors, and self-care activities for peripheral neuropathy symptoms of HIV/AIDS.

Authors:  Patrice K Nicholas; Joachim Voss; Dean Wantland; Teri Lindgren; Emily Huang; William L Holzemer; Yvette Cuca; Shahnaz Moezzi; Carmen Portillo; Suzanne Willard; John Arudo; Kenn Kirksey; Inge B Corless; María E Rosa; Linda Robinson; Mary J Hamilton; Elizabeth Sefcik; Sarie Human; Marta Rivero-Mendez; Mary Maryland; Kathleen M Nokes; Lucille Eller; Jeanne Kemppainen; Carol Dawson-Rose; John M Brion; Elli H Bunch; Maureen Shannon; Thomas P Nicholas; Ana Viamonte-Ros; Catherine A Bain
Journal:  Nurs Health Sci       Date:  2010-03       Impact factor: 1.857

3.  Injection of the sciatic nerve with TMEV: a new model for peripheral nerve demyelination.

Authors:  Kristen M Drescher; Steven M Tracy
Journal:  Virology       Date:  2006-10-09       Impact factor: 3.616

4.  Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya.

Authors:  Sapna A Mehta; Aabid Ahmed; Beatrice W Kariuki; Swaleh Said; Fanuel Omasete; Megan Mendillo; Maura Laverty; Robert Holzman; Fred Valentine; Sumathi Sivapalasingam
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

Review 5.  Genetics of HIV-associated sensory neuropathy and related pain in Africans.

Authors:  Huguette Gaelle Ngassa Mbenda; Antonia Wadley; Zane Lombard; Catherine Cherry; Patricia Price; Peter Kamerman
Journal:  J Neurovirol       Date:  2017-05-30       Impact factor: 2.643

6.  Acu/Moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study.

Authors:  Joyce K Anastasi; Bernadette Capili; Donald J McMahon; Colin Scully
Journal:  J Assoc Nurses AIDS Care       Date:  2013 May-Jun       Impact factor: 1.354

7.  Motor Axonal Neuropathy Associated With Idiopathic CD4(+) T-Lymphocytopenia.

Authors:  Tae Im Yi; Bo Ra Kim; In Soo Han; Bo Kyoung Kim
Journal:  Ann Rehabil Med       Date:  2013-02-28

8.  HIV lumbosacral radiculoplexus neuropathy mimicking lymphoma: diffuse infiltrative lymphocytosis syndrome (DILS) restricted to nerve?

Authors:  Nizar Chahin; Zelalem Temesgen; Paul J Kurtin; Robert J Spinner; P James B Dyck
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

Review 9.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  Disorder in clotting pattern after antiretroviral treatment with emtricitabine in an HIV-positive haemophiliac patient.

Authors:  Antonio Liras
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.